Antibiotic Resistance and Co** Strategies of Methicillin-Resistant Staphylococcus Species

A special issue of Antibiotics (ISSN 2079-6382). This special issue belongs to the section "Mechanism and Evolution of Antibiotic Resistance".

Deadline for manuscript submissions: 31 October 2024 | Viewed by 508

Special Issue Editor


E-Mail Website
Guest Editor
Department of Oral Microbiology, Medical Faculty, Medical University of Gdansk, 80-204 Gdansk, Poland
Interests: Staphylococcus aureus; medical microbiology; Staphylococcus; bacterial antibiotic resistance; MRSA; bacteriology; oral microbiology

Special Issue Information

Dear Colleagues,

Bacterial resistance to antimicrobial agents is currently one of the most emerging global public health problems, leading to treatment failures in many patient groups. Staphylococcus aureus and other Staphylococcus species are significant etiological factors of infection develo** multiple mechanisms of antibiotic resistance, which are transferred rapidly between the strains in both hospital and community settings. The problem is particularly evident in the case of methicillin-resistant S. aureus (MRSA), which previously spread primarily in a hospital setting as hospital-acquired MRSA (HA-MRSA) but is nowadays increasingly found in community settings as community-acquired MRSA (CA-MRSA), displaying high infectivity and virulence. Prevention of methicillin-resistant Staphylococcus species transmitted in health care facilities is a major infection control challenge. Previous antibiotic treatments used are ineffective, so exploring alternative therapies is important.

In this Special Issue, we encourage research to clarify resistance mechanisms of Staphylococcus aureus. Papers about alternative therapies to solve the resistance of Staphylococcus aureus such as phages, new antimicrobial drugs and antimicrobial combinations will be welcomed.

Dr. Katarzyna Garbacz
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at mdpi.longhoe.net by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Antibiotics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Staphylococcus aureus
  • methicillin resistance
  • MRSA
  • multidrug resistance
  • MDR
  • alternative therapies

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

11 pages, 1597 KiB  
Article
A New Guanidine-Core Small-Molecule Compound as a Potential Antimicrobial Agent against Resistant Bacterial Strains
by Noelia Morata-Moreno, Ramón Pérez-Tanoira, Almudena del Campo-Balguerias, Fernando Carrillo-Hermosilla, Marcos Hernando-Gozalo, Carlos Rescalvo-Casas, Ana V. Ocana, Pedro Segui, Carlos Alonso-Moreno, Francisco C. Pérez-Martínez and Milagros Molina-Alarcón
Antibiotics 2024, 13(7), 609; https://doi.org/10.3390/antibiotics13070609 - 29 Jun 2024
Viewed by 204
Abstract
The guanidine core has been one of the most studied functional groups in medicinal chemistry, and guanylation reactions are powerful tools for synthesizing this kind of compound. In this study, a series of five guanidine-core small molecules were obtained through guanylation reactions. These [...] Read more.
The guanidine core has been one of the most studied functional groups in medicinal chemistry, and guanylation reactions are powerful tools for synthesizing this kind of compound. In this study, a series of five guanidine-core small molecules were obtained through guanylation reactions. These compounds were then evaluated against three different strains of Escherichia coli, one collection strain from the American Type Culture Collection (ATCC) of E. coli ATCC 35218, and two clinical extended-spectrum beta-lactamase (ESBL)-producing E. coli isolates (ESBL1 and ESBL2). Moreover, three different strains of Pseudomonas aeruginosa were studied, one collection strain of P. aeruginosa ATCC 27853, and two clinical multidrug-resistant isolates (PA24 and PA35). Among Gram-positive strains, three different strains of Staphylococcus aureus, one collection strain of S. aureus ATCC 29213, and two clinical methicillin-resistant S. aureus (MRSA1 and MRSA2) were evaluated. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC) experiments were reported, and the drop plate (DP) method was used to determine the number of viable suspended bacteria in a known beaker volume. The results from this assessment suggest that guanidine-core small molecules hold promise as therapeutic alternatives for treating infections caused by clinical Gram-negative and Gram-positive bacteria, highlighting the need for further studies to explore their potential. Full article
Show Figures

Figure 1

Back to TopTop